
Opinion|Videos|April 30, 2025
Effect of Hypercortisolism on Cardiovascular and Diabetes Care
Experts discuss how hypercortisolism contributes to treatment-resistant hypertension and other cardiovascular diseases, the impact of treating hypercortisolism on cardiovascular risks, when cardiologists should suspect hypercortisolism as a contributing factor to cardiovascular disease, the role of hypercortisolism in type 2 diabetes, how it complicates the management of type 2 diabetes and impacts long-term glucose control, and when endocrinologists should suspect hypercortisolism in their patients with type 2 diabetes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does hypercortisolism contribute to treatment-resistant hypertension and other cardiovascular diseases?
- We have mentioned that there are cardiovascular risks associated with hypercortisolism. How does treatment of hypercortisolism impact these risks?
- Looking specifically from a cardiology perspective, when should a cardiologist suspect hypercortisolism as a contributing factor to cardiovascular disease?
- What is the role of hypercortisolism in type 2 diabetes?
- How does hypercortisolism complicate the management of type 2 diabetes, and how does it impact long-term glucose control?
- Now, let us shift to the endocrinology perspective. When should an endocrinologist suspect hypercortisolism in their patients with type 2 diabetes?
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

